UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer

Clinical cancer research, 2018-01, Vol.24 (2), p.316-325

2018

Volltextzugriff (PDF)

Responses and durability of clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients treated with pegilodecakin (AM0010) in combination with 5-FU/LV and oxaliplatin (FOLFOX)

Annals of oncology, 2018-10, Vol.29, p.viii406-viii406

2018

Volltextzugriff (PDF)

Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases

ESMO open, 2023-04, Vol.8 (2), p.100884-100884, Article 100884

2023

Volltextzugriff (PDF)

Thermal properties of MoSi2 and SiC whisker-reinforced MoSi2

Journal of materials science, 1992-05, Vol.27 (10), p.2749-2752

1992

Volltextzugriff (PDF)

Processing and mechanical properties of niobium-reinforced MoSi2 composites

Materials science & engineering. A, Structural materials : properties, microstructure and processing, 1991-10, Vol.144 (1-2), p.277-285

1991

Volltextzugriff (PDF)

1143PResponses and durability of clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients treated with pegilodecakin (AM0010) in combination with 5-FU/LV and oxaliplatin (FOLFOX)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Interdependencia cleptocrática: Caso de estudio El Salvador

Desafios (Bogotá, Colombia), 2016-08, Vol.28 (2), p.65-111

Gómez-Hecht, J. R, Juan Ricardo

2016

Volltextzugriff (PDF)

Gastrointestinal toxicity or irinotecan

Oncology (Williston Park, N.Y.), 1998-08, Vol.12 (8 Suppl 6), p.72

Hecht, J R

1998

Volltextzugriff (PDF)

Adjuvant therapy for gastric cancer: a reality at last

Current gastroenterology reports, 2000-12, Vol.2 (6), p.478-481

Hecht, J R

2000

Volltextzugriff (PDF)

Male breast cancer

American journal of clinical pathology, 1994-10, Vol.102 (4 Suppl 1), p.S25-S30

1994

Volltextzugriff (PDF)

Dietary fat and colon cancer

Advances in experimental medicine and biology, 1996, Vol.399, p.157

Hecht, J R

1996

Volltextzugriff (PDF)

Clostridium difficile colitis secondary to intravenous vancomycin

Digestive diseases and sciences, 1989, Vol.34 (1), p.148-149

1989

Volltextzugriff (PDF)

SPIRITT: A multicenter, open-label, randomized, phase II clinical trial evaluating safety and efficacy of FOLFIRI with either panitumumab or bevacizumab as second-line treatment in patients with metastatic colorectal cancer (mCRC) with wild-type KRAS tumors

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.TPS195-TPS195

2010

Volltextzugriff (PDF)

Development of continuous-fiber-reinforced MoSi2-base composites

Materials science & engineering. A, Structural materials : properties, microstructure and processing, 1992-07, Vol.155 (1-2), p.19-31

1992

Volltextzugriff (PDF)

Progression-free survival in intention to treat populations versus total KRAS populations in patients treated for metastatic colorectal cancer: A pooled review

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.4054-4054

2009

Volltextzugriff (PDF)

Results from the LOGiC Trial

MD conference express, 2013-07, Vol.13 (6), p.20-20

2013

Volltextzugriff (PDF)

PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.3534-3534

2010

Volltextzugriff (PDF)

Pegfilgrastim in colorectal cancer (CRC) patients (pts) receiving every-two-week (Q2W) chemotherapy (CT): Long-term results from a phase II, randomized, controlled study

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.4072-4072

2009

Volltextzugriff (PDF)

Successful Gastrointestinal Cancer Drug Development

Seminars in oncology, 2006-12, Vol.33 (6), p.24-27

Hecht, J. Randolph

2006

Volltextzugriff (PDF)

A randomized, phase IIb study of sunitinib plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) versus bevacizumab plus mFOLFOX6 as first-line treatment for metastatic colorectal cancer (mCRC): Interim results

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.3532-3532

2010

Volltextzugriff (PDF)

Pooled safety results from SPIRITT: A multicenter, open-label, randomized, phase II study of FOLFIRI with panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2011-02, Vol.29 (4_suppl), p.477-477

2011

Volltextzugriff (PDF)

Abstract PR08: Antitumor activity and immune correlates of PEGylated human IL-10 (AM0010) alone or in combination with anti-PD-1

Cancer immunology research, 2016-11, Vol.4 (11_Supplement), p.PR08-PR08

2016

Volltextzugriff (PDF)

Final results of a phase II study of modified FOLFOX6 (mFOLFOX6) and erlotinib (E) in patients with metastatic adenocarcinoma of the esophagus (Eso) and gastroesophageal junction (GEJ)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.4050-4050

2010

Volltextzugriff (PDF)

5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study

Cancer management and research, 2015-01, Vol.7 (default), p.165-173

2015

Volltextzugriff (PDF)

A multinational, randomized phase III study of bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer (CC): Subgroup analyses from the AVANT trial

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.3509-3509

2011

Volltextzugriff (PDF)

1 – 25 von 1.807

Suche als RSS-Feed

Aktive Filter

ThemaMiddle Aged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.356)
Mit Volltextzugriff
(1.605)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(944)
Life Sciences & Biomedicine
(615)
Humans
(441)
Biological And Medical Sciences
(288)
Physical Sciences
(278)
Female
(222)
Male
(209)
Medical Sciences
(190)
Animals
(183)
Physics
(127)
Biochemistry & Molecular Biology
(112)
Fundamental And Applied Biological Sciences. Psychology
(108)
Exact Sciences And Technology
(106)
Technology
(105)
Mice
(91)
Chemistry
(86)
Adult
(84)
Genetics & Heredity
(83)
Earth, Ocean, Space
(69)
Molecular Sequence Data
(67)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(14)

Menü

Weitere Dienste

Einstellungen

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer

Responses and durability of clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients treated with pegilodecakin (AM0010) in combination with 5-FU/LV and oxaliplatin (FOLFOX)

Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases

Thermal properties of MoSi2 and SiC whisker-reinforced MoSi2

Processing and mechanical properties of niobium-reinforced MoSi2 composites

1143PResponses and durability of clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients treated with pegilodecakin (AM0010) in combination with 5-FU/LV and oxaliplatin (FOLFOX)

Interdependencia cleptocrática: Caso de estudio El Salvador

Gastrointestinal toxicity or irinotecan

Adjuvant therapy for gastric cancer: a reality at last

Male breast cancer

Dietary fat and colon cancer

Clostridium difficile colitis secondary to intravenous vancomycin

SPIRITT: A multicenter, open-label, randomized, phase II clinical trial evaluating safety and efficacy of FOLFIRI with either panitumumab or bevacizumab as second-line treatment in patients with metastatic colorectal cancer (mCRC) with wild-type KRAS tumors

Development of continuous-fiber-reinforced MoSi2-base composites

Progression-free survival in intention to treat populations versus total KRAS populations in patients treated for metastatic colorectal cancer: A pooled review

Results from the LOGiC Trial

PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors

Pegfilgrastim in colorectal cancer (CRC) patients (pts) receiving every-two-week (Q2W) chemotherapy (CT): Long-term results from a phase II, randomized, controlled study

Successful Gastrointestinal Cancer Drug Development

A randomized, phase IIb study of sunitinib plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) versus bevacizumab plus mFOLFOX6 as first-line treatment for metastatic colorectal cancer (mCRC): Interim results

Pooled safety results from SPIRITT: A multicenter, open-label, randomized, phase II study of FOLFIRI with panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC)

Abstract PR08: Antitumor activity and immune correlates of PEGylated human IL-10 (AM0010) alone or in combination with anti-PD-1

Final results of a phase II study of modified FOLFOX6 (mFOLFOX6) and erlotinib (E) in patients with metastatic adenocarcinoma of the esophagus (Eso) and gastroesophageal junction (GEJ)

5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study

A multinational, randomized phase III study of bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer (CC): Subgroup analyses from the AVANT trial

Aktive Filter

Suchergebnisse filtern